Time course of reversal of anticoagulant effect of warfarin by intravenous and subcutaneous phytonadione

被引:80
作者
Raj, G
Kumar, R
McKinney, P
机构
[1] Dallas Vet Affairs Med Ctr, Gen Internal Med Sect, Dallas, TX USA
[2] Univ Texas, SW Med Ctr, Dept Med, Dallas, TX USA
[3] Univ Louisville, Div Gen Internal Med, Louisville, KY 40292 USA
关键词
D O I
10.1001/archinte.159.22.2721
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Excessive anticoagulation increases the risk of hemorrhagic complications associated with oral anticoagulant therapy. Oral or parenteral phytonadione is used to reverse excessive anticoagulation. Intravenous (IV) phytonadione, while effective, is associated with a small risk of serious anaphylactic reactions. Subcutaneous (SC) administration is safer, but there is little information on its relative efficacy in small doses. Methods: Twenty-two patients with asymptomatic prolongation of prothrombin time were prospectively randomized and treated with 1 mg of phytonadione IV or 1 mg SC. Prothrombin time was measured at baseline and at 8 and 24 hours after phytonadione administration and expressed as international normalized ratio (INR). Results: Mean INR at baseline was 8.0 and 8.5 in the IV and SC groups, respectively (P = .70). At 8 hours, mean INR was 4.6 in the IV group and 8.0 in the SC group (P = .006), and at 24 hours, mean INR was 3.1 in the IV group and 5.0 in the SC group (P = .009). Mean decrease in INR 8 hours after administration of phytonadione was 3.4 in the IV group and 0.4 in the SC group (P = .02), and mean decrease in INR after 24 hours was 4.9 in the IV group and 3.4 in the SC group (P = .18). Conclusions: For patients who are excessively anticoagulated with warfarin, small doses of SC phytonadione may not correct the INR as rapidly or as effectively as when administered IV. Higher doses must be considered for more rapid and complete reversal of anticoagulation by the SC route.
引用
收藏
页码:2721 / 2724
页数:4
相关论文
共 19 条
  • [1] ANDERSEN P, 1975, ACTA MED SCAND, V198, P269
  • [2] BARASH P, 1976, ANESTH ANALG, V55, P304
  • [3] BROPHY MT, 1995, THROMB HAEMOSTASIS, V73, P1117
  • [4] OPTIMAL ORAL ANTICOAGULANT-THERAPY IN PATIENTS WITH MECHANICAL HEART-VALVES
    CANNEGIETER, SC
    ROSENDAAL, FR
    WINTZEN, AR
    VANDERMEER, FJM
    VANDENBROUCKE, JP
    BRIET, E
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (01) : 11 - 17
  • [5] Crowther MA, 1998, THROMB HAEMOSTASIS, V79, P1116
  • [6] CONSERVATIVE TREATMENT OF OVERANTICOAGULATED PATIENTS
    GLOVER, JJ
    MORRILL, GB
    [J]. CHEST, 1995, 108 (04) : 987 - 990
  • [7] HAVEL M, 1987, CLIN THER, V9, P373
  • [8] Mechanism of action, clinical effectiveness, and optimal therapeutic range
    Hirsh, J
    Dalen, JE
    Anderson, DR
    Poller, L
    Bussey, H
    Ansell, J
    Deykin, D
    Brandt, JT
    [J]. CHEST, 1998, 114 (05) : 445S - 469S
  • [9] MECHANISM OF ACTION, CLINICAL EFFECTIVENESS, AND OPTIMAL THERAPEUTIC RANGE
    HIRSH, J
    DALEN, JE
    DEYKIN, D
    POLLER, L
    BUSSEY, H
    [J]. CHEST, 1995, 108 (04) : S231 - S246
  • [10] KOUDSTAAL PJ, 1995, NEW ENGL J MED, V333, P5